Micelle Composition for TLR7 Agonist Delivery Avoiding ABC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nanoparticle compositions for cancer treatment, particularly those containing TLR7 agonists, face challenges such as accelerated blood clearance (ABC) phenomenon due to antibody recognition, limiting their therapeutic efficacy and stability.
Innovation Solution
Development of micelle compositions comprising a TLR7 agonist, specifically 1V270, in combination with an amphiphilic micelle-forming agent like DSPE-PEG2000, which forms stable micelles that avoid accelerated blood clearance and enhance anti-cancer activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PEG-based liposomal formulations are used for TLR7 agonist delivery, then therapeutic efficacy is improved, but accelerated blood clearance occurs due to antibody recognition
Solution Approach 1:
The patent changes the fundamental parameter of the nanoparticle structure from liposomal to micellar architecture, transitioning from a bilayered membrane structure to an amphiphilic polymer core-shell structure. This structural parameter change eliminates the PEG-based surface coating that triggers ABC, while maintaining the TLR7 agonist delivery function and therapeutic efficacy.
Solution Approach 2:
The patent employs composite material design by combining amphiphilic polymers with TLR7 agonists in a micellar formulation. The amphiphilic polymer core provides structural stability and avoids immune recognition, while the TLR7 agonist is incorporated into the micelle structure for targeted immune activation, creating a synergistic composite system.
2Productivity
If repeated injections of therapeutic nanoparticle compositions are administered, then treatment efficacy is enhanced, but accelerated blood clearance phenomenon is triggered
Solution Approach 1:
The patent adopts a disposable approach by using non-PEGylated micellar formulations that do not trigger long-term immune memory or ABC phenomenon. The micelles are designed to be cleared rapidly after delivering their payload, allowing repeated administrations without accumulating immune responses, thus enabling sustained treatment efficacy without pharmacokinetic deterioration.
3Ease of operation
If traditional liposomal formulations are used, then delivery capability is achieved, but unwanted immune responses and accelerated clearance occur
Solution Approach 1:
The patent extracts and removes the problematic PEG-based surface coating and liposomal bilayer structure that are responsible for triggering ABC and unwanted immune responses. By taking out these harmful components and replacing them with amphiphilic polymer micelles, the formulation maintains delivery capability while eliminating the harmful immune responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The micelle compositions demonstrate potent anti-cancer activity with improved pharmacokinetic profiles, reducing unwanted immune responses and enhancing treatment efficacy compared to traditional liposomal formulations.
Implementation Method 1
micelle compositions comprising a TLR7 agonist, specifically 1V270, in combination with an amphiphilic micelle-forming agent like DSPE-PEG2000, which forms stable micelles
Data Source
AI summary
The present invention relates to immune stimulating nanoparticle compositions, and their use in treatment of diseases and disorders, such as cancer. In particular, the present invention relates to nanoparticle compositions comprising a TLR7 agonist, such as 1V270.5